News: AEterna Zentaris Inc (AEZ.TO)
1.90CAD
11:02am EDT
$-0.02 (-1.04%)
$1.92
$1.94
$1.94
$1.89
4,792
5,792
$5.46
$1.74
Mon, Mar 11 2013
Aeterna Zentaris to stop late-stage cancer drug trial, shares fall
- Canadian drugmaker Aeterna Zentaris Inc said it would discontinue a late-stage trial of a cancer drug after an independent data safety monitoring committee said the drug was unlikely to help increase patient survival.
Aeterna Zentaris soars on U.S. FDA trial agreement
- Shares of Aeterna Zentaris Inc jumped nearly 20 percent on Friday after the Canadian drugmaker said it has agreed with U.S. regulators on the design of a late-stage trial for its endometrial cancer treatment.
BRIEF-AEterna Zentaris stock gains premarket
NEW YORK, Dec 28 - AEterna Zentaris Inc : * AEterna Zentaris inc stock up 3.7 percent premarket in New York
Press Releases
- Aeterna Zentaris Announces Dismissal of Class Action Lawsuit
- Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO
- Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting
- Aeterna Zentaris Announces "At-the-Market" Issuance Program
- Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto
- Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders
- Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results
- Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013
- Aeterna Zentaris Newly Appointed CEO, David A. Dodd, to Host Introductory Analyst and Investor Conference Call on Thursday, April 25, 2013
- Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to Cetrotide® to Merck KGaA
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
